

## **MENDUS AB (PUBL) HAS DECIDED ON DIRECTED ISSUES OF CLASS C SHARES AND TRANSFER OF OWN ORDINARY SHARES**

**As authorized by shareholders at the Annual General Meeting on May 6, 2025, Mendus AB (publ) ("Mendus") has decided to issue and subsequently immediately repurchase Class C shares in order to facilitate payment of remuneration to board members and bonuses to employees in shares.**

In order to offer remuneration to board members and bonuses to employees in shares, as well as to preserve liquidity, at the Annual General Meeting on May 6, 2025, Mendus shareholders authorized the board of directors of Mendus to decide on directed issues of redeemable and convertible Class C shares as well as repurchase of all issued Class C shares through a directed offer to all holders of Class C shares.

Pursuant to the authorizations granted by shareholders at the Annual General meeting on May 6, 2025, the board has resolved on two directed issues of a total of 1,725,000 Class C shares to DNB Bank ASA, Sweden Branch. The subscription price in the directed issues corresponds to the quota value of the shares, which is approximately SEK 1 per share. The board has also resolved, pursuant to the authorizations granted at the Annual General Meeting on May 6, 2025, to immediately repurchase all 1,725,000 Class C shares from DNB Bank ASA, Sweden Branch at the same price as the subscription price following completion of the issue of the Class C shares and registration at the Swedish Companies Registration Office.

The Class C shares that are repurchased will be converted into ordinary shares and subsequently transferred to the board members and employees who have chosen to receive their remuneration and bonuses in the form of shares. Payment of bonuses in shares to employees pertains to the financial year 2024 and will be delivered as soon as possible. Payment of remuneration in shares to board members pertains to the current term of office and will be delivered quarterly after the remuneration has been earned.

Mendus has previously not held any Class C shares or ordinary shares. After the share issue and subsequent conversion of all Class C shares to ordinary shares, the total number of ordinary shares in Mendus will amount to 52,084,578.

### **For more information, please contact:**

Erik Manting  
Chief Executive Officer  
E-mail: [ir@mendus.com](mailto:ir@mendus.com)

### **About Mendus AB (publ)**

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>

Press Release

26 May 2025 17:50:00 CEST

